CancerDrs Find care

Endometrial Cancer clinical trials in Iowa

13 actively recruiting endometrial cancer trials at 13 sites across Iowa.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • McFarland Clinic - Boone — Boone, Iowa
  • Heartland Oncology and Hematology LLP — Council Bluffs, Iowa
  • Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ — Council Bluffs, Iowa
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07198074
Sites in Iowa:
  • Mercy Hospital — Cedar Rapids, Iowa
  • Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response …

Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT05611931
Sites in Iowa:
  • University of Iowa — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Iowa:
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • Mercy Hospital — Cedar Rapids, Iowa
  • Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
  • UI Health Care Mission Cancer and Blood - Des Moines Clinic — Des Moines, Iowa
  • Mercy Medical Center - Des Moines — Des Moines, Iowa
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Iowa:
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa
  • UI Health Care Mission Cancer and Blood - Des Moines Clinic — Des Moines, Iowa
  • Mercy Medical Center - Des Moines — Des Moines, Iowa
  • UI Health Care Mission Cancer and Blood - Laurel Clinic — Des Moines, Iowa
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Iowa:
  • University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Iowa:
  • University of Iowa — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body bes…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05208762
Sites in Iowa:
  • University of Iowa — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor ce…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05950464
Sites in Iowa:
  • University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Iowa:
  • Massive Bio SYNERGY-AI site — Iowa City, Iowa
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Iowa:
  • Methodist Jennie Edmundson Hospital — Council Bluffs, Iowa
  • Covenant Medical Center, Inc — Waterloo, Iowa
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20